Literature DB >> 3023560

Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy.

H Shimizu, N Jaffe, E Kleinerman.   

Abstract

Unexpected early epidural spinal metastasis in a case of osteosarcoma occurred in a patient receiving treatment with cis-diamminedichloroplatinum-II (cisplatin). The initial neurologic symptomatology manifested as paresthesias in the feet which developed 2 months after initiation of treatment (cumulative dose of cisplatin 450 mg/M2) at which stage the primary tumor demonstrated a marked response. Concurrently two small pulmonary metastases appeared. Epidural metastasis in osteosarcoma is generally considered a late complication and is usually associated with disseminated disease. This communication draws attention to changes in the metastatic pattern which may occur with the administration of seemingly effective treatment and the potential for confusing the symptomatology of epidural spinal metastasis with cisplatin neuropathy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023560     DOI: 10.1007/bf00165378

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report.

Authors:  A Kedar; M E Cohen; A I Freeman
Journal:  Cancer Treat Rep       Date:  1978-05

2.  Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment.

Authors:  D Hadley; H W Herr
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

3.  Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies.

Authors:  N Jaffe; J Knapp; V P Chuang; S Wallace; A Ayala; J Murray; A Cangir; A Wang; R S Benjamin
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

4.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

Authors:  S W Thompson; L E Davis; M Kornfeld; R D Hilgers; J C Standefer
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

5.  cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.

Authors:  J J Ochs; A I Freeman; H O Douglass; D S Higby; E R Mindell; L F Sinks
Journal:  Cancer Treat Rep       Date:  1978-02

6.  Intraspinal metastatic disease in childhood cancer.

Authors:  M Baten; R C Vannucci
Journal:  J Pediatr       Date:  1977-02       Impact factor: 4.406

7.  Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy.

Authors:  N Jaffe; E Smith; H T Abelson; E Frei
Journal:  J Clin Oncol       Date:  1983-04       Impact factor: 44.544

8.  Neurotoxic effects of cisplatin therapy.

Authors:  T J Walsh; A W Clark; I M Parhad; W R Green
Journal:  Arch Neurol       Date:  1982-11

9.  Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Authors:  M Gasparini; J Rouesse; A van Oosterom; T Wagener; R Somers; J A Russel; P A Voûte; V Bramwell; D Thomas; R Sylvester
Journal:  Cancer Treat Rep       Date:  1985-02

10.  Single-agent cis-platinum therapy for advanced ovarian cancer.

Authors:  D M Gershenson; J T Wharton; J Herson; C L Edwards; F N Rutledge
Journal:  Obstet Gynecol       Date:  1981-10       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.